Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1
Open Access
- 6 July 2014
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 20 (8) , 904-910
Abstract
Individuals with neurofibromatosis type-1 (NF1) can manifest focal skeletal dysplasias that remain extremely difficult to treat. NF1 is caused by mutations in the NF1 gene, which encodes the RAS GTPase–activating protein neurofibromin. We report here that ablation of Nf1 in bone-forming cells leads to supraphysiologic accumulation of pyrophosphate (PPi), a strong inhibitor of hydroxyapatite formation, and that a chronic extracellular signal–regulated kinase (ERK)-dependent increase in expression of genes promoting PPi synthesis and extracellular transport, namely Enpp1 and Ank, causes this phenotype. Nf1 ablation also prevents bone morphogenic protein-2–induced osteoprogenitor differentiation and, consequently, expression of alkaline phosphatase and PPi breakdown, further contributing to PPi accumulation. The short stature and impaired bone mineralization and strength in mice lacking Nf1 in osteochondroprogenitors or osteoblasts can be corrected by asfotase-α enzyme therapy aimed at reducing PPi concentration. These results establish neurofibromin as an essential regulator of bone mineralization. They also suggest that altered PPi homeostasis contributes to the skeletal dysplasias associated with NF1 and that some of the NF1 skeletal conditions could be prevented pharmacologically.Keywords
This publication has 65 references indexed in Scilit:
- Dose response of bone-targeted enzyme replacement for murine hypophosphatasiaBone, 2011
- Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type IHuman Molecular Genetics, 2011
- FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiationJournal of Bone and Mineral Metabolism, 2011
- Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblastsJournal of Bone and Mineral Research, 2010
- The Inorganic Pyrophosphate Transporter ANK Preserves the Differentiated Phenotype of Articular ChondrocyteJournal of Biological Chemistry, 2010
- Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chickBone, 2010
- Tumor microenvironment and neurofibromatosis type I: connecting the GAPsOncogene, 2007
- Bone Mineral Density in Children and Adolescents with Neurofibromatosis Type 1The Journal of Pediatrics, 2007
- ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiaeCell Metabolism, 2006
- Double Inactivation of NF1 in Tibial PseudarthrosisThe American Journal of Human Genetics, 2006